Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33.42 | 27.97 | 37.33 | 24.78 | 32.33 | 27.05 | 24.43 | 24.67 | 30.32 | 21.11 | 33.20 | 14.36 |
| Expenses | 24.19 | 19.76 | 20.39 | 16.65 | 21.02 | 17.14 | 14.55 | 17.37 | 20.70 | 14.38 | 21.82 | 11.01 |
| Operating Profit | 9.23 | 8.21 | 16.94 | 8.13 | 11.31 | 9.91 | 9.88 | 7.30 | 9.62 | 6.73 | 11.38 | 3.35 |
| OPM % | 27.62% | 29.35% | 45.38% | 32.81% | 34.98% | 36.64% | 40.44% | 29.59% | 31.73% | 31.88% | 34.28% | 23.33% |
| Other Income | 0.80 | 1.11 | 1.32 | 0.54 | 0.19 | 0.71 | 2.29 | 0.66 | 0.69 | 0.66 | 1.02 | 0.94 |
| Interest | 0.01 | 0.02 | 0.15 | 0.32 | 0.43 | 0.38 | 0.96 | 0.94 | 1.01 | 0.74 | 0.88 | 0.32 |
| Depreciation | 1.41 | 1.88 | 1.86 | 2.02 | 2.42 | 2.70 | 2.42 | 2.42 | 2.59 | 2.67 | 2.80 | 2.44 |
| Profit before tax | 8.61 | 7.42 | 16.25 | 6.33 | 8.65 | 7.54 | 8.79 | 4.60 | 6.71 | 3.98 | 8.72 | 1.53 |
| Tax % | 23.81% | 35.31% | 22.46% | 26.70% | 25.78% | 27.85% | 24.80% | 25.00% | 26.23% | 22.36% | 28.10% | 27.45% |
| Net Profit | 6.55 | 4.80 | 12.59 | 4.65 | 6.42 | 5.43 | 6.60 | 3.45 | 4.96 | 3.10 | 6.27 | 1.12 |
| EPS in Rs | 5.12 | 3.75 | 9.84 | 3.62 | 5.00 | 4.23 | 5.14 | 2.69 | 3.86 | 2.41 | 4.88 | 0.87 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16 | 20 | 27 | 35 | 58 | 49 | 71 | 91 | 126 | 109 | 109 | 99 |
| Expenses | 14 | 16 | 22 | 26 | 47 | 35 | 53 | 68 | 84 | 69 | 74 | 68 |
| Operating Profit | 2 | 4 | 5 | 9 | 11 | 14 | 18 | 23 | 42 | 39 | 35 | 31 |
| OPM % | 12% | 21% | 19% | 25% | 19% | 28% | 25% | 26% | 33% | 36% | 32% | 31% |
| Other Income | 0 | 0 | 2 | 1 | 4 | 2 | 4 | 1 | 3 | 4 | 3 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 4 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 4 | 6 | 10 | 10 | 10 |
| Profit before tax | 2 | 4 | 6 | 9 | 13 | 13 | 18 | 20 | 38 | 31 | 24 | 21 |
| Tax % | 34% | 33% | 28% | 28% | 24% | 25% | 26% | 25% | 26% | 26% | 26% | |
| Net Profit | 1 | 3 | 5 | 6 | 10 | 10 | 13 | 15 | 28 | 23 | 18 | 15 |
| EPS in Rs | 6.75 | 16.50 | 3.66 | 4.88 | 7.52 | 7.62 | 10.47 | 11.86 | 21.97 | 18.00 | 13.84 | 12.02 |
| Dividend Payout % | 0% | 0% | 19% | 18% | 14% | 18% | 4% | 2% | 2% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 22% | 17% | 6% | -9% | ||
| Compounded Profit Growth | 31% | 11% | 3% | -29% | ||
| Stock Price CAGR | % | 15% | 11% | 32% | ||
| Return on Equity | 19% | 18% | 17% | 11% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 9 | 9 | 9 | 10 | 12 | 13 | 13 | 13 | 13 |
| Reserves | 12 | 13 | 15 | 20 | 25 | 33 | 40 | 50 | 75 | 109 | 132 | 150 |
| Borrowings | 0 | 0 | 0 | 2 | 1 | 2 | 0 | 0 | 33 | 36 | 38 | 31 |
| Other Liabilities | 2 | 2 | 5 | 5 | 7 | 8 | 10 | 15 | 18 | 12 | 8 | 14 |
| Total Liabilities | 15 | 16 | 21 | 36 | 41 | 52 | 61 | 77 | 138 | 171 | 192 | 208 |
| Fixed Assets | 4 | 4 | 4 | 6 | 14 | 16 | 19 | 27 | 58 | 81 | 95 | 105 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 15 | 17 | 9 | 13 |
| Investments | 0 | 0 | 0 | 4 | 4 | 7 | 3 | 0 | 0 | 5 | 18 | 13 |
| Other Assets | 11 | 11 | 17 | 25 | 23 | 29 | 37 | 47 | 64 | 69 | 70 | 78 |
| Total Assets | 15 | 16 | 21 | 36 | 41 | 52 | 61 | 77 | 138 | 171 | 192 | 208 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -1 | -2 | 2 | -1 | -5 | 4 | 3 | 13 | 17 | 30 | 31 | 24 |
| Cash from Investing Activity | 1 | 1 | 0 | -3 | -0 | -3 | -1 | -12 | -51 | -33 | -35 | -9 |
| Cash from Financing Activity | -0 | -0 | -0 | 8 | -0 | -0 | -1 | -1 | 39 | 10 | -1 | -12 |
| Net Cash Flow | -1 | -0 | 2 | 4 | -5 | 1 | 2 | 0 | 5 | 7 | -6 | 3 |
| Free Cash Flow | -1 | -2 | 2 | -0 | -5 | 4 | 3 | -2 | -32 | -1 | 7 | 7 |
| CFO/OP | -58% | -79% | 44% | -18% | -60% | 35% | 24% | 75% | 73% | 92% | 104% | 81% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 93 | 133 | 136 | 78 | 101 | 104 | 99 | 94 | 112 | 59 | 75 | 109 |
| Inventory Days | 132 | 130 | 103 | 102 | 125 | 56 | 206 | 132 | 138 | 156 | 223 | 209 |
| Days Payable | 43 | 32 | 90 | 43 | 75 | 39 | 101 | 92 | 118 | 51 | 61 | 82 |
| Cash Conversion Cycle | 183 | 232 | 149 | 137 | 151 | 120 | 205 | 134 | 133 | 164 | 238 | 236 |
| Working Capital Days | 160 | 202 | 172 | 128 | 145 | 102 | 158 | 133 | 122 | 89 | 111 | 128 |
| ROCE % | 16% | 12% | 26% | 27% | 27% | 33% | 28% | 33% | 22% | 28% | 19% | 14% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 69.33% | 69.33% | 69.33% | 69.33% | 70.49% | 72.80% | 72.80% | 72.80% | 72.80% | 72.80% | 72.83% | 72.83% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.00% | 0.00% | 0.00% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.52% |
| Public | 30.67% | 30.66% | 30.67% | 30.66% | 29.50% | 27.19% | 27.20% | 27.20% | 27.19% | 27.20% | 27.16% | 26.65% |
| No. of Shareholders | 7,330 | 7,518 | 7,049 | 7,186 | 8,508 | 8,695 | 8,978 | 9,166 | 8,752 | 8,442 | 8,058 | 7,822 |
Fundamentals
Market Cap₹ 856 Cr.
Current Price₹ 666
Stock P/E55.4
Book Value₹ 127
ROCE14.2 %
ROE10.8 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-9%
Compounded Profit Growth (TTM)-29%
Standalone figures.
Valuation
Market capRs 891 Cr
Enterprise valueRs 909 Cr
P/E (TTM)57.69x
Price to book5.47x
Price to sales9.00x
EV / EBITDA26.42x
EV / EBIT38.03x
EV / sales9.18x
Price to cash flow37.53x
Earnings yield1.73%
P/E, 3-year average33.45x
P/B, 3-year average5.54x
P/E, 5-year average29.57x
P/B, 5-year average5.21x
Profitability
Operating margin (excl. other income)32.13%
Operating margin (incl. other income)34.82%
EBITDA margin34.74%
Pre-tax margin21.15%
Net profit margin15.61%
Net margin, latest quarter7.80%
ROE11.53%
ROCE14.62%
ROA8.89%
ROE, 3-year average18.56%
ROCE, 3-year average20.65%
ROA, 3-year average13.28%
ROE, 5-year average20.02%
ROCE, 5-year average23.37%
ROA, 5-year average14.68%
ROIC (approx.)9.80%
Tax rate25.98%
Other income / net worth1.80%
Growth
Sales growth (latest year)0.64%
Profit growth (latest year)-23.07%
Sales CAGR, 3 years6.16%
Sales CAGR, 5 years17.38%
Profit CAGR, 3 years5.39%
Profit CAGR, 5 years12.76%
Sales growth QoQ-56.75%
Profit growth QoQ-82.14%
Sales growth YoY (latest quarter)-41.79%
Profit growth YoY (latest quarter)-67.54%
Per share
EPS (TTM)Rs 12.03
EPS (latest year)Rs 13.84
EPS (latest quarter)Rs 0.87
EPS, 3-year averageRs 17.91
EPS, 5-year averageRs 15.34
Book value per shareRs 126.99
Sales per shareRs 77.11
Cash flow per shareRs 18.50
Free cash flow per shareRs 5.45
Dividend per share, 3-year averageRs 0.50
Dividend per share, 5-year averageRs 0.43
Dividends
Dividend payout, 3-year average2.28%
Dividend payout, 5-year average3.09%
Efficiency
Asset turnover0.53x
Fixed asset turnover1.04x
Inventory turnover2.14x
Inventory days170 days
Debtor days109 days
Debtors turnover3.36x
Creditor days82 days
Cash conversion cycle236 days
Working capital days128 days
Leverage
Total debtRs 31 Cr
Cash and bankRs 13 Cr
Net debtRs 17 Cr
Debt to equity0.19x
Net debt / EBITDA0.50x
Interest coverage8.10x
Owners' fund to total sources78.48%
Debt to assets14.83%
Cash flow
Cash from Operating Activity (latest year)Rs 24 Cr
Cash from Investing Activity (latest year)Rs -9 Cr
Cash from Financing Activity (latest year)Rs -12 Cr
Net Cash Flow (latest year)Rs 3 Cr
Free cash flow (latest year)Rs 7 Cr
FCFE (approx.: FCF + change in debt)Rs -1 Cr
Cash from ops / profit, 5 years1.19x
Sales to cash flow4.60x
Statement figures
Net sales (TTM)Rs 99 Cr
Net sales (latest year)Rs 109 Cr
Sales (latest quarter)Rs 14 Cr
Operating profit excl. other income (latest year)Rs 35 Cr
Operating profit (latest quarter)Rs 3 Cr
Other income (TTM)Rs 3 Cr
EBITDA (TTM)Rs 34 Cr
PBDT (TTM)Rs 31 Cr
Profit before tax (TTM)Rs 21 Cr
Tax (latest year)Rs 6 Cr
Net profit (TTM)Rs 15 Cr
Net profit (latest year)Rs 18 Cr
Net profit (latest quarter)Rs 1 Cr
Depreciation (TTM)Rs 10 Cr
Depreciation (latest quarter)Rs 2 Cr
Interest (TTM)Rs 3 Cr
Cost of goods sold (latest year)Rs 51 Cr
Total expenditure (latest year)Rs 74 Cr
Total income (latest year)Rs 112 Cr
Share capitalRs 13 Cr
ReservesRs 150 Cr
Shareholders' fundsRs 163 Cr
Total assetsRs 208 Cr
Net blockRs 105 Cr
Capital work in progressRs 13 Cr
InvestmentsRs 13 Cr
ReceivablesRs 33 Cr
InventoryRs 24 Cr
Other liabilitiesRs 14 Cr
Shares outstanding (crore)1.28
Ownership
Promoter holding72.83% (+0.03 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 57.7 is at the 96th percentile of its own 9.1-year range
(median 28.8, low 9.2, high 59.1).
P/B 5.47 is at the 58th percentile (median 5.10).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | SGRL | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +2.5% | -2.8% | +5.3 pts |
| 1 month | +1.4% | -6.8% | +8.2 pts |
| 3 years | +42.7% | +14.2% | +28.6 pts |
| 5 years | +109.2% | +27.9% | +81.3 pts |
1 mutual fund schemes hold about ₹0 Cr.
Over three months 0 bought more and 0 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Bandhan BSE Healthcare Index Fund | 0.01% | 0 |
Red flags
F-score 5 of 8| explain | Receivables outrunning sales Receivables grew 46% vs sales +1% in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹14 Cr -41.8% vs Jun 2025.
Net profit ₹1 Cr -67.5%.
Against our estimate for Jun 2026: sales -45.6%, profit -72.7% miss. Our estimate for Sep 2026: sales Rs 29 Cr, profit Rs 5 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Shree Ganesh Remedies Ltd?
Shree Ganesh Remedies Ltd (SGRL) has a market capitalisation of Rs 856 Cr. at the 2026-10-01 close.
What is the P/E ratio of Shree Ganesh Remedies Ltd?
Shree Ganesh Remedies Ltd trades at a P/E of 55.4 on trailing twelve-month profit, at the 2026-10-01 close.
What were Shree Ganesh Remedies Ltd's latest quarterly results?
In the Jun 2026 quarter, Shree Ganesh Remedies Ltd sales was Rs 14 Cr (-41.8% vs Jun 2025) and net profit was Rs 1 Cr.
What is the 52-week high and low of Shree Ganesh Remedies Ltd?
The 52-week high is Rs 749.85 and the 52-week low is Rs 477.05.